Donated human brains may soon be studied for two weeks

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

An up to $28.3 million ARPA-H award aims to stretch Bexorg’s human brain platform from 24 hours to two weeks.

A day is a long time to study a donated human brain. Bexorg thinks it’s still too short.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3226

Bexorg

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 4: Longevity clinical services
    Professionally qualified clinics that offer diagnosis of health and aging biomarkers; clinical guidance on lifestyle, diet and therapeutic interventions to mitigate the progression of age.
  • Level 2: Consumer diagnostics
    Companies that analyze biological samples (normally blood), lifestyle questionnaires, digital information and apply AI to identify opportunities for both clinical and lifestyle interventions to improve healthspan.

Overview

Bexorg is a clinical-stage techbio company developing an integrated artificial intelligence and whole-human brain platform for central nervous system drug discovery and development. The company's proprietary BrainEx system restores metabolic and molecular activity in donated human brains, enabling researchers to test drug candidates in a living human neural environment before clinical trials. By combining perfusion technology with advanced machine learning models trained on comprehensive human brain datasets, Bexorg aims to reduce CNS drug development failures and accelerate the discovery of therapeutics for neurodegenerative diseases including Alzheimer's and Parkinson's disease.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE